Literature DB >> 35612906

Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use.

Benjamin Y C Cheong1,2, James M Wilson3, Ourania A Preventza4,5, Raja Muthupillai2,6.   

Abstract

Gadolinium-based contrast agents have expanded the diagnostic usefulness and capability of magnetic resonance imaging. Despite their highly favorable safety profile, these agents have been associated with nephrogenic systemic fibrosis in a small number of patients who have advanced kidney disease. Recently, trace amounts of gadolinium deposition in the brain and other organs have been reported after contrast exposure, even in patients with normal renal function. In this review, we provide a brief overview of recent updates and discuss typical clinical situations related to the use of gadolinium-based contrast agents.
© 2022 by the Texas Heart® Institute, Houston.

Entities:  

Keywords:  Acute kidney injury/complications; gadolinium/administration & dosage/adverse effects; image enhancement/methods; kidney failure, chronic/complications; kidney/diagnostic imaging; magnetic resonance imaging; nephrogenic fibrosing dermopathy/chemically induced/prevention & control; practice guidelines as topic; renal dialysis; risk factors

Mesh:

Substances:

Year:  2022        PMID: 35612906      PMCID: PMC9242635          DOI: 10.14503/THIJ-21-7680

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  43 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

Review 2.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

3.  Nephrogenic fibrosing dermopathy.

Authors:  S E Cowper; L D Su; J Bhawan; H S Robin; P E LeBoit
Journal:  Am J Dermatopathol       Date:  2001-10       Impact factor: 1.533

4.  Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.

Authors:  Diego R Martin; Saravanan K Krishnamoorthy; Bobby Kalb; Khalil N Salman; Puneet Sharma; John D Carew; Phillip A Martin; Arlene B Chapman; Gaye L Ray; Christian P Larsen; Thomas C Pearson
Journal:  J Magn Reson Imaging       Date:  2010-02       Impact factor: 4.813

Review 5.  Risk factors for NSF: a literature review.

Authors:  Martin R Prince; Hong Lei Zhang; Giles H Roditi; Tim Leiner; Walter Kucharczyk
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

6.  Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House.

Authors:  Jerry Yee
Journal:  Adv Chronic Kidney Dis       Date:  2017-05       Impact factor: 3.620

Review 7.  Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.

Authors:  Ashkan Heshmatzadeh Behzadi; Yize Zhao; Zerwa Farooq; Martin R Prince
Journal:  Radiology       Date:  2017-08-25       Impact factor: 11.105

8.  Gadolinium periconceptional exposure: pregnancy and neonatal outcome.

Authors:  M De Santis; G Straface; A F Cavaliere; B Carducci; A Caruso
Journal:  Acta Obstet Gynecol Scand       Date:  2007       Impact factor: 3.636

9.  No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.

Authors:  Jitka Starekova; Richard J Bruce; Elizabeth A Sadowski; Scott B Reeder
Journal:  Radiology       Date:  2020-09-29       Impact factor: 11.105

10.  Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.

Authors:  Henrik J Michaely; Manuela Aschauer; Hannes Deutschmann; Georg Bongartz; Matthias Gutberlet; Ramona Woitek; Birgit Ertl-Wagner; Walter Kucharczyk; Renate Hammerstingl; Francesco De Cobelli; Martin Rosenberg; Thomas Balzer; Jan Endrikat
Journal:  Invest Radiol       Date:  2017-01       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.